The Borealis-2 Clinical Trial: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Cancer Research Network GU12-160

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

• T.K. Choueiri, N.M. Hahn, S.K. Pal, A.S. Alva, R. Dreicer, A. Starodub, G. Sonpavde, J. H. Hoffman-Censits, J. Picus, A.V. Balar, E.A. Guancial, M.M. Regan, C. Jacobs, P.S. Stewart, J.E. Rosenberg. The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer. Hoosier Oncology Group GU12-160. Accepted as a TiP poster at the genitourinary (non-prostate) cancer general poster session at the ASCO Annual Meeting, May 30 – June 3, 2014, Chicago, Ill. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4593^). See abstract.
• Choueiri TK, Hahn NM, Alva AS, Lauer RC, Dreicer R, Picus J, Pili R, Balar AV, Sonpavde G, Hoffman-Censits JH, Guancial EA, Alter R, Regan MM, Jacobs C, Stewart PS, Pal SK, Rosenberg JE, BOREALIS-02 Investigators. The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (Apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer: Hoosier Cancer Research Network GU12-160. Accepted as a TiP poster at the genitourinary (non-prostate) cancer general poster session at the ASCO Annual Meeting, May 29 – June 2, 2015, Chicago, Ill. J Clin Oncol 33:5s, 2015 (suppl; abstr TPS4577). See abstract.
• Toni K. Choueiri, Noah M. Hahn, Lillian Werner, Meredith M. Regan, Jonathan E. Rosenberg. Borealis-2: A randomized phase II study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial cancer (mUC) (Hoosier Cancer Research Network GU12-160). Accepted to Poster Session B at the ASCO 2017 Genitourinary Cancers Symposium, February 16-18, 2017, Orlando, Fla. J Clin Oncol 35, 2017 (suppl 6S; abstract 289). See abstract.